If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results